首页> 外文OA文献 >Establishment and characterization of an infectious cDNA clone of a classical swine fever virus LOM strain
【2h】

Establishment and characterization of an infectious cDNA clone of a classical swine fever virus LOM strain

机译:猪瘟病毒LOM毒株传染性cDNA克隆的建立与鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Classical swine fever virus (CSFV) causes a highly contagious disease among swine that has an important economic impact worldwide. CSFV strain LOM is an attenuated virus of low virulent strain of Miyagi isolated from Japan in 1956. Eight DNA fragments representing the genome of the CSFV strain LOM were obtained by RT-PCR. These were used to determine the complete nucleotide sequence and construct a full-length cDNA clone which was called Flc-LOM. Sequence analysis of the recombinant clone (Flc-LOM) revealed the presence of eight mutations, resulting in two amino acid substitutions, when compared to the parental sequence. RNA transcripts of both LOM and Flc-LOM were directly infectious in PK-15 cells. The rescued Flc-LOM virus grew more slowly than the parental virus, LOM, in the cells. Intramuscular immunization with Flc-LOM was safe and highly immunogenic in pigs; no clinical signs or virus transmission to sentinel animals were observed after 35 days. CSFV-specific neutralizing antibodies were detected 14 days post-infection. After challenge with the virulent CSFV strain SW03, pigs immunized with Flc-LOM were shown to be fully protected. Thus, our newly established infectious clone of CSFV, Flc-LOM, could serve as a vaccine candidate.
机译:古典猪瘟病毒(CSFV)在猪中引起高度传染性疾病,在全世界范围内都具有重要的经济影响。 CSFV株LOM是1956年从日本分离的宫城县低毒力低毒株的减毒病毒。通过RT-PCR获得了代表CSFV株LOM基因组的8个DNA片段。这些被用来确定完整的核苷酸序列并构建全长cDNA克隆,称为Flc-LOM。重组克隆(Flc-LOM)的序列分析表明,与亲本序列相比,存在八个突变,导致两个氨基酸取代。 LOM和Flc-LOM的RNA转录本都直接感染PK-15细胞。拯救的Flc-LOM病毒在细胞中的生长速度比亲本病毒LOM慢。 Flc-LOM肌内免疫在猪中是安全的,具有高度免疫原性。 35天后未观察到临床体征或病毒向前哨动物的传播。感染后14天检测到CSFV特异性中和抗体。用强毒的CSFV株SW03攻击后,显示用Flc-LOM免疫的猪受到充分保护。因此,我们新建立的CSFV传染性克隆Flc-LOM可作为候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号